UGT1A1＊28基因多态性与FOLFIRI方案化疗致迟发性腹泻的关系

Relationship between UGTIA1 ＊ 28 gene polymorphism and delayed diarrhea caused by FOLFIRI treatment

目的探讨尿苷二磷酸葡糖苷酸转移酶1A1（UGT1A1）基因多态性与FOLFIRI方案化疗致迟发性腹泻的关系。方法选取晚期消化道肿瘤患者201例，在FOLFIRI方案化疗前抽取外周血进行UGT1A1＊28基因检测，观察并记录出现迟发性腹泻的情况。分析基因多态性与化疗致3级以上迟发性腹泻的关系。结果201例晚期消化道肿瘤患者中UGT1A1＊28纯合野生型TA6/6占77.11%（155/201），突变型TA6/7和TA7/7共占22.89%（46/201），野生型和突变型1、2级腹泻发生率分别为45.16%（70/155）和39.13%（18/46），3、4级腹泻发生率分别为9.68%（15/155）和19.57%（9/46）。基因突变型患者3、4级迟发性腹泻的发生率与野生型患者相比差异无统计学意义（χ^2=3.318，P=0.190）。结论在采用FOLFIRI方案化疗的晚期消化道肿瘤患者中，UGT1A1＊28基因突变型并未增加患者发生3级以上迟发性腹泻的风险。

ObjectiveTo analyze the relationship between UDPglucuronosyltransferase 1A1 （UGT1A1） gene polymorphism and delayed diarrhea caused by FOLFIRI treatment. MethodsTwo hundred and one blood samples were taken from patients with metastatic digestive tract tumor before chemotherapy by FOLFIRI and then the UGT1A1＊28 genetic polymorphism was performed. All the cases treated with FOLFIRI were chosen to be observed and recorded by situation of the delayed diarrhea during chemotherapy, and to analyze the relationship between UGT1A1＊28 genetic polymorphism and grade 3 and 4 delayed diarrhea. ResultsThe distributions of the genotypes in 201 metastatic digestive tract tumor patients were as follows： UGT1A1＊28 wildtype genotype TA6/6 （155, 77.11%）, heterozygous genotype TA6/7 together with homozygous genotype TA7/7 （46, 22.89%）. In the 201 cases, the incidences of grade 1 and 2 delayed diarrhea in the patients carrying wildtype genotype and mutant type were respectively 45.16% （70/155）, 39.13% （18/46）. The incidences of grade 3 and 4 delayed diarrhea were respectively 9.68% （15/155）, 19.57% （9/46）, with no statistical difference （χ^2=3.318, P=0.190）. ConclusionThe UGT1A1＊28 polymorphism TA6/7 or TA7/7 can not increase the risk of grade 3 or more severe delayed diarrhea for the patients with metastatic digestive tract tumor after receiving FOLFIRI treatment.